Please login to the form below
CALD gene therapy
This page shows the latest CALD gene therapy news and features for those working in and with pharma, biotech and healthcare.
EMA accepts application for bluebird bio’s Lenti-D in CALD
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential
Latest news
-
Bluebird Bio reveals further encouraging data for CALD gene therapy
Study shows continued benefit in treatment of rare disease. Last year, Bluebird Bio claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – it has now ... Lenti-D is Bluebird’s lead gene
-
Bluebird bags breakthrough status for CALD gene therapy
News comes after impressive data from a phase II/III trial. Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare ... Bluebird’s gene therapy approach could do away
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
